Transcutaneous Vagus Nerve Stimulation (tcVNS) in JIA

Juvenile Idiopathic Arthritis (JIA) Clinical Trial

— AJA01  

Official title:

Using the Cholinergic Anti-Inflammatory Pathway to Treat Juvenile Idiopathic Arthritis (AJA01)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05710640
• Other study ID #: DAIT AJA01
• Status: Recruiting
• Phase: Phase 2
• Start date: June 27, 2023
• Est. completion date: August 1, 2025

Study information

• Verified date: May 2024
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a multicenter, double-blind, sham-controlled trial to evaluate the safety and effectiveness of tcVNS on pain and inflammation associated with JIA. tcVNS is administered with a device that gives off mild electrical impulses through the skin to stimulate the vagus nerve. Part of the vagus nerve and its branches are located in the head and neck. For this study, the impulses will be administered in areas overlying the vagus nerve using a small electrode. The electrode helps to conduct the stimulation through the skin. This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.

The primary objective of this study is to determine the effect of tcVNS on JIA ACR 50 in participants with active JIA. The components of the active and sham tcVNS devices, utilizing the Roscoe Medical TENS 7000, have been FDA 510(k)-cleared and have been determined by the IRB to be a nonsignificant risk device.

Description:

AJA01 is a multicenter, double-blind, sham-controlled, 16-week trial to evaluate the safety and effectiveness of tcVNS for the treatment of JIA.

A total of 100 participants will be randomized 1:1 to treatment with active tcVNS or sham tcVNS for 5 minutes once a day for 8 weeks. During this time, participants/parents, and participant assessors will be blinded to treatment assignment; treatments on clinic visit days will be conducted in the clinic under the supervision of a trained, unblinded staff member, and participants will only discuss the stimulation procedure with this staff member. An unblinded site investigator will follow up on any safety events. The double-blind, sham-controlled 8-week period will be followed by an 8-week open-label period in which all participants will receive treatment with active tcVNS once a day for 5 minutes. Participants and their parents will be told it is likely they will feel the stimulation, but it should not be painful.

There are 10 visits for the study, 8 clinic visits and 2 tele-visits. Participants will have physical exams with joint assessments, lab tests, and questionnaire completion by the physicians and participants at each clinic visit. Participants will be trained by the unblinded coordinator to perform stimulation during the clinic visit following the randomization. Participants will perform the stimulation at home for 5 minutes daily. Participants will complete a diary to document the daily stimulation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: August 1, 2025
• Est. primary completion date: August 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 18 Years

Eligibility

Inclusion Criteria:

1. Participant is 5 through 18 years of age (inclusive) at screening.

2. Regarding informed consent and compliance:

1. If 5 through 6 years of age, the participant's guardian is willing and able to understand and provide informed consent and comply with study protocol.

2. If 7 through 17 years of age, the participant is willing and able to sign assent and comply with study protocol, and the participant's guardian is willing and able to understand and provide informed consent and comply with study protocol.

3. If 18 years of age, the participant is willing and able to understand and provide informed consent and comply with study protocol.

3. The participant has a Juvenile Idiopathic Arthritis (JIA) diagnosis meeting International League of Associations for Rheumatology (ILAR) classification criteria with one of the following subtypes:

1. rheumatoid-factor negative polyarthritis

2. rheumatoid-factor positive polyarthritis

3. persistent oligoarthritis

4. extended oligoarthritis

5. psoriatic arthritis

6. enthesitis-related arthritis

7. systemic arthritis

4. The participant has >=3 joints with active arthritis at screening

5. If the participant is receiving therapy for JIA at screening, that therapy is stable for the time period outlined below and is expected to remain stable for the duration of the study:

a. stable dose for at least 1 week prior to screening: i. Oral steroids, <= 0.2 mg/kg/day with a maximum 10 mg/day dose

b. stable dose for at least 2 weeks prior to screening: i. NSAIDs

c. stable dose for at least 8 weeks prior to screening: i. adalimumab ii. anakinra iii. canakinumab iv. certolizumab pegol v. etanercept vi. golimumab vii. infliximab viii. leflunomide ix. methotrexate x. tocilizumab

d. stable dose for at least 12 weeks prior to screening: i. abatacept

6. If a female of child-bearing potential, the participant has a negative urine pregnancy test at screening

7. If of reproductive potential, must agree to abstinence or effective methods of birth control for the duration of the study

Exclusion Criteria:

1. Other than NSAIDs or intra-articular injections, participant has been treated for JIA with lack of efficacy with:

1. More than 2 different classes of therapies, or

2. More than 3 medications in total

2. Participant has received high-dose steroids (>=0.2 mg/kg/day) within the 28 days prior to screening.

3. Participant has had active systemic disease (fever, systemic rash) within the 3 months prior to screening including any of the following lab manifestations at screening:

1. Ferritin >1000 ng/mL

2. White blood cell (WBC) =15,000/mm^3

4. Participant has had an active acute systemic infection within 2 weeks of screening. involving fever (100.4°F or higher) for more than 24 hours, requirement for systemic antibiotics or antivirals, GI symptoms lasting 48 hours or more, or the need to hold second line medications for JIA (methotrexate or biologic).

5. Participant has a history of arrhythmia.

6. Participant has been diagnosed with postural orthostatic tachycardia syndrome (POTS).

7. Participant has received an intra-articular cortisone injection within the 28 days prior to screening.

8. Participant has received treatment with an investigational drug or device during the 28 days prior to screening or within five half-lives of the investigational drug prior to screening/baseline, whichever is the greater length of time.

9. Participant has received chronic treatment with an anti-cholinergic medication, including over the counter medications.

10. Participant has received treatment with rituximab:

1. Within one year of screening

2. At any time previously without documented B cell repletion

11. Participant has a comorbid disease that has required treatment with corticosteroids within the past year.

12. Participant has an implantable electronic device such as a pacemaker, defibrillator, hearing aid, cochlear implant, insulin pump or deep brain stimulator.

13. Participant has used cutaneous vagus nerve stimulation within 12 weeks prior to screening.

14. Participant has received a live attenuated viral vaccine within 28 days prior to screening or is expected to receive one during the study.

15. Participant has any condition which, in the opinion of the investigator, would jeopardize the participant's safety following exposure to a study intervention.

16. Participant has any past or current medical problems or findings from a physical examination or laboratory testing that are not listed above but which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or may impact the quality or interpretation of the data obtained from the study.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Juvenile
• Juvenile Idiopathic Arthritis (JIA)

Intervention

Device:
• Active tcVNS or Sham tcVNS
tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
• Active tcVNS
tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.

Locations

Country	Name	City	State
United States	Emory University, Children's Healthcare of Atlanta- Center for Advanced Pediatrics: Division of Rheumatology	Atlanta	Georgia
United States	University of Chicago, Comer Children's Hospital	Chicago	Illinois
United States	Indiana University	Indianapolis	Indiana
United States	Cohen Children's Medical Center, Northwell Health	Lake Success	New York
United States	Hospital for Special Surgery	New York	New York
United States	Stephen D. Hassenfield Children's Center at NYU Langone Health	New York	New York
United States	Nemours Children's Health: Department of Pediatric Rheumatology	Orlando	Florida
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Division of Pediatric Rheumatology at the University of Utah School of Medicine and Primary Children's Hospital	Salt Lake City	Utah
United States	University of California San Francisco	San Francisco	California
United States	Seattle Children's Hospital	Seattle	Washington

Sponsors (3)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence (ACE), Feinstein Institute for Medical Research (FIMR)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of participants achieving >= 50 percent improvement in clinical status as defined by JIA ACR 50	This primary endpoint will be compared between the active tcVNS and Sham tcVNS treatment arms. The Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 50 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analog scale); parent/patient assessment of overall well-being (measured on a 10 cm visual analog scale); a validated measure of physical function Childhood Health Assessment Questionnaire (CHAQ); a laboratory measure of inflammation c-Reactive Protein (CRP); The JIA ACR 50 is achieved if 3 of any 6 core set variables improve by at least 50 percent from baseline or Day 0 visit, and no more than 1 variable worsening by >30 percent	At Week 8
Secondary	Day 0 as the baseline: The proportion of participants achieving a JIA ACR 50 response		At Weeks 4, 12, and 16
Secondary	Day 0 as the baseline: The proportion of participants achieving a JIA ACR 30 response		At Weeks 4, 8, 12, and 16
Secondary	Day 0 as the baseline: The proportion of participants achieving a JIA ACR 70 response		At Weeks 4, 8, 12, and 16
Secondary	Day 0 as the baseline: The change in Juvenile Disease Activity Score-27 (JADAS-27)	JADAS-27 is a validated composite disease activity measure for JIA. The JADAS-27 score was derived from four components; 1) Physician Global Assessment of Disease Activity (assessed on a VAS of 0 [no activity] to 10 [extreme activity]), 2) Parent/Patient Global Assessment (assessed on a VAS of 0 [very well] to 10 [very poor]), 3) Number of joints with active disease, 4) CRP (measured in milligram per liter [mg/L] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.	At Weeks 4, 8, 12, and 16
Secondary	Week 8 as the baseline: The proportion of participants achieving a JIA ACR 50 response		At Weeks 12 and 16
Secondary	Week 8 as the baseline: The proportion of participants achieving a JIA ACR 30 response		At Weeks 12 and 16
Secondary	Week 8 as the baseline: The proportion of participants achieving a JIA ACR 70 response		At Weeks 12 and 16
Secondary	Week 8 as the baseline: The change in Juvenile Disease Activity Score-27 (JADAS-27)	JADAS-27 is a validated composite disease activity measure for JIA. The JADAS-27 score was derived from four components; 1) Physician Global Assessment of Disease Activity (assessed on a VAS of 0 [no activity] to 10 [extreme activity]), 2) Parent/Patient Global Assessment (assessed on a VAS of 0 [very well] to 10 [very poor]), 3) Number of joints with active disease, 4) CRP (measured in milligram per liter [mg/L] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.	At Weeks 12, and 16
Secondary	Longitudinal trends in Juvenile Arthritis Disease Activity Score-27 (JADAS-27)	JADAS-27 is a validated composite disease activity measure for JIA. The JADAS-27 score was derived from four components; 1) Physician Global Assessment of Disease Activity (assessed on a VAS of 0 [no activity] to 10 [extreme activity]), 2) Parent/Patient Global Assessment (assessed on a VAS of 0 [very well] to 10 [very poor]), 3) Number of joints with active disease, 4) CRP (measured in milligram per liter [mg/L] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.	From Day 0 to Week 16
Secondary	Incidence of Adverse Events (AEs) and Severe Adverse Events (SAEs)		From Day 0 to Week 16

External Links

•   Autoimmunity Centers of Excellence (ACE)